## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claim 1 (currently amended): The use of A method of treating inflammation, rheumatoid arthritis and/or pain comprising administering a compound of formula I,

$$X \longrightarrow (CR_aR_a')_n \longrightarrow Y$$

$$A = B$$

$$T \longrightarrow R_1$$

$$R_2$$

$$D - E Q)_r$$

$$(I)$$

wherein

r is 0 to 2,

n is 0 to 3

R<sub>1</sub> and R<sub>2</sub>

- a) are independently in each case a lower alkyl;
- b) together form a bridge of subformula I\*,

$$(\frac{\overline{Z}_{2}}{2} - Z)_{m}$$
 (I\*)

wherein the bond is achieved via the two terminal C atoms and m is 0 to 4, or

c) together form a bridge of subformula I\*\*,

wherein one or two of the ring members  $T_1$ ,  $T_2$ ,  $T_3$  and  $T_4$  are nitrogen, and the others are in each case CH, and the bond is achieved via atoms  $T_1$  and  $T_4$ ;

G is -C(=O)-, -CHF-, -CF<sub>2</sub>-, lower alkylene, C<sub>2</sub>-C<sub>6</sub>alkenylene, lower alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-), imino (-NH-), -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>- or -CH<sub>2</sub>-NH-CH<sub>2</sub>-;

A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N;

Q is lower alkyl, lower alkoxy or halogen;

R<sub>a</sub> and R<sub>a</sub>' are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, alkylphenylsulfonyl, or (alternatively or, in a broader aspect of the invention, in addition) selected from the group consisting of ureido, halolower alkylthio, halo-lower alkansulfonyl, pyrazolyl, lower-alkyl pyrazolyl and  $C_2$ - $C_7$ alkenyl; wherein – if more than 1 radical Z ( $m \ge 2$ ) is present – the substituents Z are selected independently from each other;

and wherein the bonds characterized in subformula I\* by a wavy line are either single or double bonds;

or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a pharmaceutically acceptable salt thereof[[,]].

for the manufacture of a pharmaceutical preparation for the treatment of an inflammatory rheumatic or rheumatoid disease and/or pain.

Claim 2 (currently amended): The <u>use\_method\_according</u> to claim 1, where in the compound of the formula I, or the salt thereof,

r is 0 to 2,

n is 0 to 3

R₁ and R₂

- a) are independently in each case a lower alkyl;
- b) together form a bridge of subformula I\*,

wherein the bond is achieved via the two terminal C atoms and

m is 0 to 4, or

c) together form a bridge of subformula I\*\*,

wherein one or two of the ring members  $T_1$ ,  $T_2$ ,  $T_3$  and  $T_4$  are nitrogen, and the others are in each case CH, and the bond is achieved via atoms  $T_1$  and  $T_4$ ;

G is -C(=O)-, -CHF-, -CF<sub>2</sub>-, lower alkylene, C<sub>2</sub>-C<sub>6</sub>alkenylene, lower alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-), imino (-NH-), -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>- or -CH<sub>2</sub>-NH-CH<sub>2</sub>-;

A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N;

Q is lower alkyl, especially methyl;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, alkylphenylsulfonyl, or (alternatively or, in a broader aspect of the invention, in addition) selected from the group consisting of ureido, halo-lower alkylthio, halo-lower alkansulfonyl, pyrazolyl, lower-alkyl pyrazolyl and C<sub>2</sub>-C<sub>7</sub>alkenyl;

wherein – if more than 1 radical Z ( $m \ge 2$ ) is present – the substituents Z are selected independently from each other;

and wherein the bonds characterized in subformula I\* by a wavy line are either single or double bonds;

or an N-oxide of the defined compound, wherein 1 or more N atoms carry an oxygen atom.

Claim 3 (currently amended): The use <u>method</u> according to claim 1, where in the compound of the formula I, or the salt thereof,

r is 0 to 2,

n is 0 to 2,

m is 0 to 4,

R<sub>1</sub> and R<sub>2</sub>

- (i) are lower alkyl, especially methyl, or
- (ii) together form a bridge in subformula I\*,

the binding being achieved via the two terminal carbon atoms, or

(iii) together form a bridge in subformula I\*\*,

wherein one or two of the ring members  $T_1$ ,  $T_2$ ,  $T_3$  and  $T_4$  are nitrogen, and the others are in each case CH, and the binding is achieved via  $T_1$  and  $T_4$ .

A, B, D, and E are, independently of one another, N or CH, with the stipulation that not more than 2 of these radicals are N;

T is nitrogen;

G is lower alkylene, lower alkylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, oxa (-O-), thia (-S-), or imino (-NH-);

Q is lower alkyl, especially methyl;

R<sub>a</sub> and R<sub>a</sub>' are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is aryl, pyridyl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, or alkylphenylsulfonyl, wherein – if more than 1 radical Z (m = ≥ 2) is present – the substituents Z are are selected independently from one another;

and wherein the bonds characterized, if present, by a wavy line are either single or double bonds;

or an N-oxide of the defined compound, wherein 1 or more N atoms carry an oxygen atom.

Claim 4 (currently amended): The use method according to claim 1, where the compound of the formula I is selected from the group of compounds consisting of

1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine;

[4-(4-chloroanilino)phthalazin-1-yl](pyridin-4-yl)methanol; and

1-(4-chloroanilino) 4-[(1-oxypyridin-4-yl)methyl]phthalazine;

or a pharmaceutically acceptable salt thereof.

Claim 5 (canceled).

Claim 6 (original): A compound of formula I,

wherein

r is 0 to 2,

n is 0 to 2,

R<sub>1</sub> and R<sub>2</sub>

- a) are independently in each case a lower alkyl;
- b) together form a bridge of subformula I\*,

wherein the bond is achieved via the two terminal C atoms and

m is 0 to 4, or

c) together form a bridge of subformula I\*\*,

wherein one or two of the ring members  $T_1$ ,  $T_2$ ,  $T_3$  and  $T_4$  are nitrogen, and the others are in each case CH, and the bond is achieved via atoms  $T_1$  and  $T_4$ ;

G represents

- i) C<sub>2</sub>-C<sub>6</sub>alkenylene, C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-), imino (-NH-), -C(=O)-, -CHF- or -CF<sub>2</sub>-; or
- ii) C<sub>2</sub>-C<sub>6</sub>alkylene if Q is lower alkyl, or
- iii) C<sub>1</sub>-C<sub>6</sub>alkylene if Q is lower alkoxy or halogen;

A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N, and that T is only N when  $\alpha$ ) G is C<sub>2</sub>-C<sub>6</sub>alkenylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, or  $\beta$ ) when Q is lower alkoxy or halogen;

Q is lower alkyl, lower alkoxy or halogen;

R<sub>a</sub> and R<sub>a</sub>' are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, or alkylphenylsulfonyl, wherein – if more than 1 radical Z (m ≥ 2) is present – the substituents Z are selected independently of each other. and wherein the bonds characterized in subformula I\* by a wavy line are either single or double bonds:

or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a salt thereof.

Claim 7 (original): A compound of formula I according to claim 6,

wherein

r is 0 to 2.

n is 0 to 2,

R₁ and R₂

- a) are independently in each case a lower alkyl;
- b) together form a bridge of subformula I\*,

wherein the bond is achieved via the two terminal C atoms and

m is 0 to 4, or

c) together form a bridge of subformula I\*\*,

wherein one or two of the ring members  $T_1$ ,  $T_2$ ,  $T_3$  and  $T_4$  are nitrogen, and the others are in each case CH, and the bond is achieved via atoms  $T_1$  and  $T_4$ ;

G is C<sub>2</sub>-C<sub>6</sub>alkylene, C<sub>2</sub>-C<sub>6</sub>alkenylene, C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-), imino (-NH-), -C(=O)-, -CHF- or -CF<sub>2</sub>-;

A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N, and that T is only N when G is C<sub>2</sub>-C<sub>6</sub>alkenylene or is C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy;

Q is lower alkyl;

Ra and Ra' are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, or alkylphenylsulfonyl, wherein – if more than 1 radical Z (m ≥ 2) is present – the substituents Z are selected independently of each other. and wherein the bonds characterized in subformula I\* by a wavy line are either single or double bonds;

or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a salt thereof.

Claim 8 (original): A compound of formula I according to claim 6,

wherein

r is 0 to 2,

n is 0 to 2,

R₁ and R₂ either

- a) are independently in each case a lower alkyl;
- b) or together form a bridge in subformula I\*,

wherein the bond is achieved via the two terminal C atoms and

m is 0 to 4, or

c) together form a bridge in subformula I\*\*,

wherein one or two of the ring members  $T_1$ ,  $T_2$ ,  $T_3$  and  $T_4$  are nitrogen, and the others are in each case CH, and the bond is achieved via atoms  $T_1$  and  $T_4$ ;

G is C<sub>2</sub>-C<sub>6</sub>alkylene, C<sub>2</sub>-C<sub>6</sub>alkenylene, C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-) or imino (-NH-);

A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N, and that T is only N when G is C<sub>2</sub>-C<sub>6</sub>alkenylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy;

Q is lower alkyl;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, or alkylphenylsulfonyl, wherein − if more than 1 radical Z (m ≥ 2) is present − the substituents Z are chosen independently of each other; and wherein the bonds characterized by a wavy line are either single or double bonds; or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a salt thereof.

Claim 9 (original): A compound of formula I according to claim 6, wherein r is 0 to 2,

n is 0 to 2.

R<sub>1</sub> and R<sub>2</sub> together form a bridge in subformula I\*,

m is 0 to 4.

G is C<sub>2</sub>-C<sub>6</sub>alkylene, C<sub>2</sub>-C<sub>6</sub>alkenylene, C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, oxa (-O-), thia (-S-) or imino (-NH-);

A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N, and that T is only N when G is C<sub>2</sub>-C<sub>6</sub>alkenylene or is C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy;

Q is lower alkyl;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower

alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, or alkylphenylsulfonyl, wherein – if more than 1 radical Z ( $m \ge 2$ ) is present – the substituents Z are selected independently from one another:

and wherein the bonds characterized by a wavy line are either single or double bonds; or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a salt thereof.

Claim 10 (original): A compound of formula I according to claim 6, wherein r is 0 to 2.

n is 0 to 2,

 $R_{1}$  and  $R_{2} together form a bridge in subformula <math display="inline">I^{\star},$ 

m is 0 to 4,

G is C<sub>2</sub>-C<sub>6</sub>alkylene, C<sub>2</sub>-C<sub>6</sub>alkenylene, C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, oxa (-O-), thia (-S-) or imino (-NH-);

A, B, D, and E are, independently of one another, N or CH, subject to the proviso that not more than 2 of these radicals are N, and T is CH;

Q is lower alkyl;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino, oxa, or thia;

Y is aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, or alkylphenylsulfonyl, wherein – if more than 1 radical Z ( $m \ge 2$ ) is present – the substituents Z are selected independently from one another:

and wherein the bonds characterized by a wavy line are either single or double bonds; or an N-oxide of the defined compound, wherein 1 or more N atoms carry an oxygen atom; or a salt thereof.

Claim 11 (original): A compound of formula I according to claim 6, wherein r is 0 or 1.

n is 0 or 1,

 $R_1$  and  $R_2$  together form a bridge in subformula I\*, m is 0 or 1,

G represents

- i) C<sub>2</sub>-C<sub>6</sub>alkenylene, C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, -CH<sub>2</sub>-O-, -CH<sub>2</sub>-S-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-O-CH<sub>2</sub>-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-CH<sub>2</sub>-, oxa (-O-), thia (-S-), imino (-NH-), -C(=O)-, -CHF- or -CF<sub>2</sub>-; or
- ii) C<sub>2</sub>-C<sub>6</sub>alkylene if Q is lower alkyl, or
- iii) C<sub>1</sub>-C<sub>6</sub>alkylene if Q is lower alkoxy or halogen;
- A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N, and that T is only N when  $\alpha$ ) G is C<sub>2</sub>-C<sub>6</sub>alkenylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, or  $\beta$ ) when Q is lower alkoxy or halogen;

R<sub>a</sub> and R<sub>a</sub>' are each independently H or lower alkyl;

Q is lower alkyl, lower alkoxy or halogen;

X is imino, oxa, or thia,

- Y is phenyl, which is unsubstituted or is substituted independently by one or two substituents from the group consisting of amino; lower alkanoylamino, halogen, lower alkyl, halogen-lower alkyl, lower alkoxy, phenyl-lower alkoxy, cyano, lower alkenyl, C<sub>8</sub>-C<sub>12</sub>alkoxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, lower alkanoyl, phenyloxy, halogen-lower alkyloxy, lower alkoxycarbonyl, lower alkylmercapto, halogen-lower alkylmercapto, hydroxylower alkyl, lower alkylsulfonyl, halogen-lower alkylsulfonyl, phenylsulfonyl, dihydroxybora, 2-methylpyrimidin-4-yl, oxazol-5-yl, 2-methyl-1,3-dioxolan-2-yl, 1H-pyrazol-3-yl, 1-methylpyrazol-3-yl, and lower alkylenedioxy bound to two adjacent C atoms;
- Z is amino; N-lower alkylamino; hydroxy-lower alkylamino; phenyl-lower alkylamino; N,N-di-lower alkylamino; n-phenyl-lower alkyl-N-lower alkylamino; N,N-di-lower alkylphenylamino; lower alkanoylamino; or a substituent from the group consisting of benzoylamino and phenyl-lower alkoxycarbonylamino, wherein the phenyl radical in each case is unsubstituted or substituted by nitro, halogen, amino, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl or carbamoyl; or is halogen; and, the bonds characterized by a wavy line in each case represent a double bond or in the broader sense also a single bond;

or a salt thereof.

Claim 12 (original):. A compound of formula I according to claim 6, wherein

r is 0 or 1,

n is 0 or 1, \_

R<sub>1</sub> and R<sub>2</sub> together form a bridge in subformula I\*,

m is 0 or 1,

B, E, D and T are each CH and A is N;

G is C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>2</sub>-C<sub>6</sub>alkenylene;

Q is methyl;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino, oxa, or thia,

Y is phenyl, which is unsubstituted or is substituted independently by one or two substituents from the group consisting of amino; lower alkanoylamino, halogen, lower alkyl, halogen-lower alkyl, lower alkoxy, phenyl-lower alkoxy, cyano, lower alkenyl, C<sub>8</sub>-C<sub>12</sub>alkoxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, lower alkanoyl, phenyloxy, halogen-lower alkyloxy, lower alkoxycarbonyl, lower alkylmercapto, halogen-lower alkylmercapto, hydroxylower alkyl, lower alkylsulfonyl, halogen-lower alkylsulfonyl, phenylsulfonyl, dihydroxybora, 2-methylpyrimidin-4-yl, oxazol-5-yl, 2-methyl-1,3-dioxolan-2-yl, 1H-pyrazol-3-yl, 1-methylpyrazol-3-yl, and lower alkylenedioxy bound to two adjacent C atoms;

Z is amino; N-lower alkylamino; hydroxy-lower alkylamino; phenyl-lower alkylamino; N,N-di-lower alkylamino; n-phenyl-lower alkyl-N-lower alkylamino; N,N-di-lower alkylphenylamino; lower alkanoylamino; or a substituent from the group consisting of benzoylamino and phenyl-lower alkoxycarbonylamino, wherein the phenyl radical in each case is unsubstituted or substituted by nitro, halogen, amino, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl or carbamoyl; or is halogen; and,

the bonds characterized by a wavy line in each case represent a double bond or in the broader sense also a single bond;

or a salt thereof.

Claim 13 (original): A compound of formula I according to claim 6, wherein

r is 0 or 1.

n is 0 or 1,

R<sub>1</sub> and R<sub>2</sub> together form a bridge in subformula I\*,

m is 0;

B, E, D and T are each CH and A is N;

G is C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>2</sub>-C<sub>6</sub>alkenylene;

Q is methyl;

Ra and Ra' are each independently H or lower alkyl;

X is imino, oxa, or thia,

Y is phenyl, which is unsubstituted or is substituted independently by one or two substituents selected from the group consisting of amino; lower alkanoylamino; halogen, lower alkyl; halogen-lower alkyl; lower alkoxy; phenyl-lower alkoxy; cyano; lower alkenyl, C<sub>8</sub>-C<sub>12</sub>alkoxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, lower alkanoyl, phenyloxy, halogen-lower alkyloxy, lower alkoxycarbonyl, lower alkylmercapto, halogen-lower alkylmercapto, hydroxy-lower alkyl, lower alkylsulfonyl, halogen-lower alkylsulfonyl, phenylsulfonyl, dihydroxybora, 2-methylpyrimidin-4-yl, oxazol-5-yl, 2-methyl-1,3-dioxolan-2-yl, 1H-pyrazol-3-yl, 1-methylpyrazol-3-yl, and lower alkylenedioxy bound to two adjacent C atoms;

the bonds characterized by a wavy line in each case represent a double bond or in the broader sense also a single bond;

or a salt thereof.

Claim 14 (original): A compound of formula I according to claim 6, wherein

r is 0;

n is 0:

R<sub>1</sub> and R<sub>2</sub> together form a bridge in subformula I\*,

m is 0;

A, B, D, E and are each independently N or CH subject to the proviso that at least one oan don't more than three of these radicals are N, and that T is only N when α) G is C<sub>2</sub>-C<sub>6</sub>alkylene or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy, or β) when Q is lower alkoxy or halogen;

G is ethylene, propylene or ethenylene;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino,

Y is phenyl, which is unsubstituted or substituted by one or two substituents selected independently from the group consisting of halogen; lower alkyl; and halogen-lower alkyl; and the bonds characterized by a wavy line are double bonds; or a salt thereof.

Claim 15 (original): A compound of formula I according to claim 6, wherein r is 0;

n is 0;

R<sub>1</sub> and R<sub>2</sub> together form a bridge in subformula I\*,

m is 0:

G is ethylene, propylene or ethenylene;

A is N and B, D, E and T are CH;

R<sub>a</sub> and R<sub>a</sub> are each independently H or lower alkyl;

X is imino:

Y is phenyl, which is unsubstituted or substituted by one or two substituents selected independently from the group consisting of lower alkyl; halogen; and trifluoromethyl; and the bonds characterized by a wavy line are either single or double bonds; or an N-oxide of said compound, wherein one or more N atoms carry an oxygen atom; or a salt thereof.

Claim 16 (original): A compound of formula I according to claim 11, wherein

r is 1;

n is 0;

R<sub>1</sub> and R<sub>2</sub> together form a bridge in subformula I\*,

m is 0;

G is methylene;

T is N and A, B, D, and E are CH;

Q is lower alkoxy or halogen;

X is imino;

Y is phenyl, which is substituted by one or two substituents selected independently from the group consisting of lower alkyl; lower alkoxy; halogen; and trifluoromethyl; and the bonds characterized by a wavy line are double bonds; or an N-oxide of said compound, wherein one or more N atoms carry an oxygen atom; or a salt thereof.

Claim 17 (original): 1-(3-Methylanilino)-4-[(2-(pyridin-3-yl)ethyl]phthalazine of formula I according to claim 6, or a pharmaceutically acceptable salt thereof.

Claim 18 (original): A compound of formula I according to claim 6, selected from the group consisting of

E-1-(3-methylanilino)-4-[(2-(pyridin-3-yl)vinyl]phthalazine,

- Z-1-(3-methylanilino)-4-[(2-(pyridin-3-yl)vinyl]phthalazine,
- 1-(3-methylanilino)-4-[(2-(pyridin-3-yl)ethyl]phthalazine,
- 1-(3-methylanilino)-4-[(2-(pyridin-4-yl)vinyl]phthalazine,
- 1-(4-chloro-3-trifluoromethylanilino)-4-[(2-(pyridin-3-yl)ethyl]phthalazine,
- 1-(4-chloroanilino)-4-[(2-(pyridin-3-yl)ethyl]phthalazine,
- 1-(3-chlorobenzylamino)-4-[(2-(pyridin-3-yl)ethyl]phthalazine,
- 1-(4-chloro-3-trifluoromethylanilino)-4-[3-(pyridin-3-yl)propyl]phthalazine,
- 1-(4-chloroanilino)-4-[3-(pyridin-3-yl)propyl]phthalazine,
- 1-(3-chloro-5-trifluoromethylanilino)-4-[3-(pyridin-3-yl)propyl]phthalazine, and
- 1-(4-tert-butylanilino)-4-[3-(pyridin-3-yl)propyl]phthalazine,
- or in each case a pharmaceutically acceptable salt thereof.

Claim 19 (canceled).

Claim 20 (original): A pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 6 to 18, together with at least one pharmaceutically acceptable carrier.

Claim 21 (canceled).

Claim 22 (canceled).

- Claim 23 (original): A method for the preparation of a compound of formula I according to claim 6, comprising
- a) for the preparation of a compound of formula I, in which G is -CH<sub>2</sub>-O-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>-S-, -O-, -S-, or -NH-, reacting a compound of formula II,

wherein A, B, D, E, T, G, Q, R<sub>1</sub>, and R<sub>2</sub> are as defined for a compound of formula I and L is a nucleofugal leaving group, with a compound of formula III

$$H-X-(CR_aR_a')_n-Y$$
 (III)

wherein n, Ra, Ra', X, and Y are as defined for a compound of formula I;

b) for the preparation of a compound of formula I, in which G is lower alkylene, especially C<sub>2</sub>-C<sub>6</sub>alkylene, C<sub>2</sub>-C<sub>6</sub>-alkenylene; or lower alkylene, especially C<sub>2</sub>-C<sub>6</sub>alkylene, or C<sub>3</sub>-C<sub>6</sub>alkenylene substituted by acyloxy or hydroxy; reacting a compound of formula IV,

wherein n,  $R_a$ ,  $R_a$ , X, Y,  $R_1$  and  $R_2$  are as defined for a compound of formula I, and  $R_4$  is H or alkyl, in the presence of a base with a compound of formula V

wherein r, A, B, D, E, T and Q are as defined for a compound of formula I, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are independently alkyl or H, j represents a whole number between 0 and 5, and Ph is phenyl,

and reacting the resulting compound of formula I with  $G = -CR_4 = CR_7 - (CR_5R_6)_j$  if so desired by hydrogenation with side-group metal catalysis or addition of water and possibly subsequent acylation to form a different compound of formula I;

c) for the preparation of a compound of formula I in which G is -CH<sub>2</sub>-O-CH<sub>2</sub>-, reacting a compound of formula IV\*,

$$N = \begin{pmatrix} X - (CR_aR_a')_n - Y \\ N - R_1 \\ R_2 \end{pmatrix}$$
(IV\*)

wherein n,  $R_a$ ,  $R_a$ , X, Y,  $R_1$  and  $R_2$  are as defined for a compound of formula I, in the presence of a base with a compound of formula VI,

wherein r, A, B, D, E, T and Q are as defined for a compound of formula I and Hal is halogen;

d) for the preparation of a compound of formula I in which G is -CH<sub>2</sub>-S-CH<sub>2</sub>-, reacting a compound of formula IV\*\*,

$$N = \begin{array}{c} X-(CR_aR_a')_{n^-} & Y \\ N = \begin{array}{c} N = \\ R_1 \end{array}$$

$$R_8-O_2S-O = \begin{array}{c} R_2 \end{array} \qquad (IV^{**})$$

wherein n, R<sub>a</sub>, R<sub>a</sub>', X, Y, R<sub>1</sub> and R<sub>2</sub> are as defined for a compound of formula I and R<sub>8</sub> is alkyl, for example methyl, or alkylaryl, for example tolyl, with a compound of formula VII

wherein r, A, B, D, E, T and Q are as defined for a compound of formula I and M<sup>+</sup> is a metal cation containing a single charge, for example a sodium or potassium cation;

e) for the preparation of a compound of formula I in which G is -CH<sub>2</sub>-NHCH<sub>2</sub>-, reacting a compound of formula IV\*\*\*,

wherein n,  $R_a$ ,  $R_a$ , X, Y,  $R_1$  and  $R_2$  are as defined for a compound of formula I, with a compound of formula  $V^*$ ,

wherein r, A, B, D, E, T and Q are as defined for a compound of formula I, in the presence of hydrogen and a catalyst;

wherein in compounds of formulae I to VII, IV\*, IV\*\*, IV\*\*\* and V\*, functional groups which do not participate in the reaction are present in protected form where necessary,

and removing any protective groups present, whereas said starting compounds may also be present in the form of salts if a salt-forming group is present and the reaction in salt form is possible;

and, if so desired, converting an obtainable compound of formula I or an N-oxide thereof into another compound of formula I or an N-oxide thereof, converting a free compound of formula I or an N-oxide thereof into a salt, converting an obtainable salt of a compound of formula I or an N-oxide thereof into the free compound or another salt, and/or separating a mixture of isomeric compounds of formula I or N-oxides thereof into the individual isomers.

## Claim 24 (original): A compound of the formula IA

$$X \longrightarrow (CR_aR_a')_n \longrightarrow Y$$

$$A = B$$

$$T \longrightarrow R_1$$

$$CR_aR_a')_n \longrightarrow Y$$

$$R_1$$

$$R_2$$

$$D - E \longrightarrow Q)_r$$

$$R_2$$

$$R_3$$

$$R_4$$

$$R_2$$

$$R_3$$

wherein

r is 0 to 2, especially 0 or 1;

n is 0 to 3;

R<sub>1</sub> and R<sub>2</sub> together form a bridge as shown in subformula I\*\*\*,

$$CH$$
 $Z_1$ 
 $CH$ 
 $Z_2$ 
 $(I^{***})$ 

wherein either each of  $Z_1$  and  $Z_2$  is hydrogen, or one is hydrogen, the other methyl;

the binding being achieved via the two terminal CH groups in subformula I\*\*\* and to the two adjacent carbon atoms binding R<sub>1</sub> and R<sub>2</sub> in formula IA, so that a six-membered ring is formed;

A, B, D and E are CH and T is N,

Q is methyl (preferably bound to A and/or D);

G is -C(=O)-, -CHF- or  $-CF_2$ -;

each of R<sub>a</sub> and R<sub>a</sub>' is hydrogen;

X is imino;

Y is 4-chlorophenyl, 4-tert-butyl-phenyl, 3,5-dimethyl-phenyl, 2-methyl-6-ethyl-phenyl, 3isopropyl-5-methyl-phenyl, 3-ureido-phenyl, 3-chloro-4-methoxy-phenyl, 4-chloro-3-methoxyphenyl, 3-methoxy-4-methyl-phenyl, 3-methoxy-4-ethyl-phenyl, 3-(trifluoromethylthio)-phenyl, 6-chloro-3-(trifluoromethylsulfonyl)-phenyl, 3-(N-methylcarbamoyl)-phenyl, 4-(N-tertbutylcarbamoyl)-phenyl, 3-(pyrazol-3-yl)-phenyl, 3-([1-methyl-pyrazol]-3-yl)-phenyl, 4-(tertbutoxycarbonyl)-phenyl, 3,5-bis(methoxycarbonyl)-phenyl, 3-vinyl-phenyl, 3,4- or 3,5-bis(trifluoromethyl)-phenyl, 3-chloro-4-methyl-phenyl, 3-bromo-4-methyl-phenyl, 3-bromo-4-ethylphenyl, 4-bromo-3-isopropyl-phenyl, 4-bromo-3-n-propyl-phenyl, 3-iodo-4-methylphenyl, 4iodo-3-isopropyl-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3-chloro-5-trifluoromethyl-phenyl, 4-chloro-3-trifluoromethyl-phenyl, 3-bromo-5-trifluoromethyl-phenyl, 4-bromo-3-trifluoromethyl-phenyl, 4-iodo-3-trifluormethyl-phenyl, 3-bromo-5-(2,2,2-trifluoroethyl)-phenyl, 3-iodo-5-trifluoromethyl-phenyl, 3-methyl-5-trifluoromethylphenyl or 4-sulfamoyl-phenyl, or (especially if n is other than 0) is 4-methylphenyl, 3-methylphenyl, 4-ethyl-phenyl, 3-ethylphenyl, 2-methylphenyl, 3- or 4-trifluoromethyl-phenyl, 2-chlorophenyl, 3-chlorophenyl or 3fluoro-5-trifluoromethyl-phenyl, or is 2-naphthyl; quinolin-6-yl; 5-methyl-pyridin-2-yl; 6-methyl-pyridin-2-yl; 4-methylpyrimidin-

or is 2-naphthyl; quinolin-6-yl; 5-methyl-pyridin-2-yl; 6-methyl-pyridin-2-yl; 4-methylpyrimidin-2-yl; 6-tert-butyl-pyrimidin-4-yl; 5-trifluoromethyl-pyridin2-yl; 5-methoxy-pyridin-2-yl; 2,6-dimethyl-pyridin-4-yl or 4,6-dimethyl-pyridin-2-yl; 2,6-dimethyl-pyrimidin-4-yl; 5-bromo-pyridin-2-yl or 6-chloro-pyridin-3-yl;

or is 4-tertbutylcyclohexyl;

or an N-oxide thereof, wherein 1 or more nitrogen atoms carry an oxygen atom; or a salt thereof.

Claim 25 (original): A compound of the formula IA according to claim 24, wherein

r is 0 to 2, especially 0 or 1;

n is 0 to 3;

R<sub>1</sub> and R<sub>2</sub> together form a bridge as shown in subformula I\*\*\*,

$$CH$$
  $Z_1$   $CH$   $Z_2$   $(I^{***})$ 

wherein either each of  $Z_1$  and  $Z_2$  is hydrogen, or one is hydrogen, the other methyl; the binding being achieved via the two terminal CH groups in subformula I\*\*\* and to the two adjacent carbon atoms binding  $R_1$  and  $R_2$  in formula IA, so that a six-membered ring is formed;

A, B, D and E are CH and T is N,

Q is methyl (preferably bound to A and/or D);

G is methylene or hydroxymethylene;

each of R<sub>a</sub> and R<sub>a</sub>' is hydrogen;

X is imino;

Y is 3-isopropyl-5-methyl-phenyl, 4-chloro-3-methoxy-phenyl, 3,4-bis(trifluoromethyl)-phenyl, 3-chloro-4-methyl-phenyl, 3-bromo-4-methyl-phenyl, 3-bromo-4-ethyl-phenyl, 4-bromo-3-isopropyl-phenyl, 4-bromo-3-n-propyl-phenyl, 3-iodo-4-methylphenyl, 4-iodo-3-isopropyl-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3-chloro-5-trifluoromethyl-phenyl, 4-bromo-3-trifluoromethyl-phenyl, 4-iodo-3-trifluormethyl-phenyl, 3-bromo-5-(2,2,2-trifluoroethyl)-phenyl, 3-iodo-5-trifluoromethyl-phenyl, 3-methyl-5-trifluoromethylphenyl or 4-sulfamoyl-phenyl, or (if n is other than 0) is 4-methylphenyl, 3-methylphenyl, 4-ethyl-phenyl, 3-ethyl-phenyl, 2-methylphenyl, 3- or 4-trifluoromethyl-phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chloro-5-trifluoromethyl-phenyl, 3-bromo-5-trifluoromethyl-phenyl or 3-fluoro-5-trifluoromethyl-phenyl,

or is 2-naphthyl; quinolin-6-yl; 5-methyl-pyridin-2-yl; 6-methyl-pyridin-2-yl; 4-methylpyrimidin-2-yl; 6-tert-butyl-pyrimidin-4-yl; 5-trifluoromethyl-pyridin-2-yl; 5-methoxy-pyridin-2-yl; 2,6-dimethyl-pyridin-4-yl or 4,6-dimethyl-pyridin-2-yl; 2,6-dimethyl-pyrimidin-4-yl; 5-bromo-pyridin-2-yl or 6-chloro-pyridin-3-yl;

or is 4-tertbutylcyclohexyl;

or an N-oxide thereof, wherein 1 or more nitrogen atoms carry an oxygen atom; or a salt thereof.

Claim 26 (original): A compound of the formula IA according to claim 24, where the compound is selected from the group consisting of the following compounds, or a pharmaceutically acceptable salt thereof:

1-(3-Bromo-4-methyl-anilino)-4-(pyridin-4-yl-methyl)-phthalazine (see example 13h below); [4-(4-chloroanilino)phthalazin-1-yl]-(pyridin-4-yl)ketone;

[4-(4-chloroanilino)phthalazin-1-yl]-(1-oxypyridin-4-yl)methanol.

Claim 27 (original): A compound of the formula IA according to claim 24,

wherein

r is 0:

and

n is 0;

R<sub>1</sub> and R<sub>2</sub> together form a bridge as shown in subformula I\*\*\*,

wherein one of  $Z_1$  and  $Z_2$  is hydrogen, the other methyl;

the binding being achieved via the two terminal CH groups in subformula I\*\*\* and to the two adjacent carbon atoms binding R<sub>1</sub> and R<sub>2</sub> in formula IA, so that a six-membered ring is formed;

A, B, D and E are CH and T is N,

G is methylene;

X is imino; and

Y is 4-chlorophenyl, 4-chloro-3-methoxy-phenyl, 3-iodo-4-methyl-phenyl, 4-chloro-3-trifluoromethyl-phenyl, 3-bromo-5-trifluoromethyl-phenyl or 4-bromo-3-trifluoromethyl-phenyl; or an N-oxide thereof, wherein 1 or more nitrogen atoms carry an oxygen atom; or a salt thereof.

Claim 28 (original): A compound of the formula IA according to claim 24,

wherein

r is 1;

n is 0:

R<sub>1</sub> and R<sub>2</sub> together form a bridge as shown in subformula I\*\*\*,

wherein each of  $Z_1$  and  $Z_2$  is hydrogen;

the binding being achieved via the two terminal CH groups in subformula  $I^{***}$  and to the two adjacent carbon atoms binding  $R_1$  and  $R_2$  in formula IA, so that a six-membered ring is formed;

A, B, D and E are CH and T is N,

G is methylene;

X is imino; and

Y is 4-chloro-3-trifluoromethyl-phenyl, 3-chloro-5-trifluoromethylphenyl, 4-tert-butylphenyl, 3-bromo-4-methyl-phenyl, 3-bromo-4-ethylphenyl or 4,5-bis(trifluoromethyl)-phenyl; or an N-oxide thereof, wherein 1 or more nitrogen atoms carry an oxygen atom; or a salt thereof.

- Claim 29 (currently amended): A method for the diagnostic or therapeutic treatment of the human body comprising administering a compound of formula IA, or a pharmaceutically acceptable salt thereof, according to claim 24 any one of claims 24 to 28 for use in a method for the diagnostic or therapeutic treatment of the human or animal body.
- Claim 30 (original): A pharmaceutical composition, comprising a compound of formula IA or a pharmaceutically acceptable salt thereof according to <u>claim 24</u> any one of claims 24 to 28, together with at least one pharmaceutically acceptable carrier.
- Claim 31 (currently amended): Use of a A method for treating a disease which responds to an inhibition of angiogenesis comprising administering a compound of formula IA according to any one of claims 24 to 28 claim 24, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of angiogenesis.
- Claim 32 (currently amended): Use of a A method for treating a disease which responds to an inhibition of VEGF-receptor kinase comprising administering a compound of formula I according to any one of claims 24 to 28 claim 24, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of VEGF-receptor kinase.